Head & Neck Cancer Drugs Market Size, Trends, Growth & Outlook

Head & Neck Cancer Drugs Market by Drug Class (Chemotherapy, Immunotherapy, and Targeted Therapy) and Sales Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Stores): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Industry: Life Science | Report ID: FAMI-00233 | Published on: Sep, 2019 | View: 773 | Share:         

Request Sample Enquire Before Buying Request Discount

*As the coronavirus disease (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

  • Report Descripton
  • Table Of Content
  • Request Methodology
  • Request Customization

The global head & neck cancer drugs market was valued at $1,295 million in 2017, and is projected to reach $2,281 million by 2025, registering a CAGR of 7.3% from 2018 to 2025. 

Head & neck cancers include a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses, lips, salivary glands and mouth. Head and neck squamous cell carcinoma (HNSCC) is the most common form of head & neck cancer, which develops in the mucous membranes of the mouth, nose, and throat. Chemotherapy, immunotherapy & targeted therapy are used for the treatment of head & neck cancer along with the radiation & surgical procedures. 

There is an increase in the demand for head & neck cancer drugs owing to the growth in incidence of head & neck cancer, rise in demand for combination therapeutics, higher number of R&D studies, and surge in adoption of immune therapeutics. In addition, growth in the geriatric population and technological advancements in screening & diagnosis of head & neck cancer further drive the market growth. Strong presence of late-stage pipeline drugs such as Ipilimumab, Atezolizumab, Avelumab, Durvalumab, Erlotinib, Afatinib, Bevacizumab, and others are expected to drive the market growth. However, higher cost & adverse effect associated with head & neck cancer drugs are projected to impede the market growth.  

The global head & neck cancer drugs market is segmented based on drug class, sales channel, and region. Based on drug class, the market is classified as chemotherapy, immunotherapy, and targeted therapy. According to the sales channel, the market is categorized as hospital pharmacies, drug stores and retail pharmacies, and online stores. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and rest of LAMEA).

Key Benefits for Head & Neck Cancer Drugs Market:

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.

It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities. 

A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.

The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

Head & Neck Cancer Drugs Key Market Segments:

By Drug Class 

Chemotherapy
Immunotherapy 
Targeted Therapy

By Sales Channel 

Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Stores 

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy 
Spain
Rest of Europe
Asia-Pacific
Japan
China 
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa 
Rest of LAMEA

List of Key Players Profiled in the  Report:

AstraZeneca PLC
Bristol-Myers Squibb Company
Eli Lilly and Company (ARMO Biosciences.)
Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)
F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
Immutep Limited
Merck & Co., Inc.
Merck KGaA (EMD Serono, Inc.)
Novartis AG
Pfizer Inc.

List of Other Players in the  Value Chain (These players are not profiled in the report. The same will be included on request.)

Boehringer Ingelheim
AVEO Pharmaceuticals"
 

Get a sample pages of this report Click here

"CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top player positioning

3.3. MARKET DYNAMICS

3.3.1. Drivers

3.3.1.1. Surge in incidence of head and neck cancer worldwide
3.3.1.2. Surge in global geriatric population
3.3.1.3. Increase in consumption of tobacco and alcohol

3.3.2. Restraints

3.3.2.1. Adverse effects associated with the use of head and neck cancer drugs

3.3.3. Opportunities

3.3.3.1. Untapped emerging economies
3.3.3.2. Increase in number of pipeline drugs

3.3.4. Impact Analyses

CHAPTER 4: HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Chemotherapy

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country

4.3. Immunotherapy

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country

4.4. Targeted therapy

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country

CHAPTER 5: HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL

5.1. Overview

5.1.1. Market size and forecast

5.2. Hospital pharmacy

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Online providers

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Drug stores & retail pharmacies

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

CHAPTER 6: HEAD & NECK CANCER DRUGS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country

6.2.2.1. U.S.

6.2.2.1.1. U.S. head & neck cancer drugs market, by drug class
6.2.2.1.2. U.S. head & neck cancer drugs market, by sales channel

6.2.2.2. Canada

6.2.2.2.1. Canada head & neck cancer drugs market, by drug class
6.2.2.2.2. Canada head & neck cancer drugs market, by sales channel

6.2.2.3. Mexico

6.2.2.3.1. Mexico head & neck cancer drugs market, by drug class
6.2.2.3.2. Mexico head & neck cancer drugs market, by sales channel

6.2.3. North America market size and forecast, by drug class
6.2.4. North America market size and forecast, by sales channel

6.3. Europe

6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe market size and forecast, by country

6.3.2.1. Germany

6.3.2.1.1. Germany head & neck cancer drugs market, by drug class
6.3.2.1.2. Germany head & neck cancer drugs market, by sales channel

6.3.2.2. France

6.3.2.2.1. France head & neck cancer drugs market, by drug class
6.3.2.2.2. France head & neck cancer drugs market, by sales channel

6.3.2.3. UK

6.3.2.3.1. UK head & neck cancer drugs market, by drug class
6.3.2.3.2. UK head & neck cancer drugs market, by sales channel

6.3.2.4. Italy

6.3.2.4.1. Italy head & neck cancer drugs market, by drug class
6.3.2.4.2. Italy head & neck cancer drugs market, by sales channel

6.3.2.5. Spain

6.3.2.5.1. Spain head & neck cancer drugs market, by drug class
6.3.2.5.2. Spain head & neck cancer drugs market, by sales channel

6.3.2.6. Rest of Europe

6.3.2.6.1. Rest of Europe head & neck cancer drugs market, by drug class
6.3.2.6.2. Rest of Europe head & neck cancer drugs market, by sales channel

6.3.3. Europe market size and forecast, by drug class
6.3.4. Europe market size and forecast, by sales channel

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Japan head & neck cancer drugs market, by drug class
6.4.2.1.2. Japan head & neck cancer drugs market, by sales channel

6.4.2.2. China

6.4.2.2.1. China head & neck cancer drugs market, by drug class
6.4.2.2.2. China head & neck cancer drugs market, by sales channel

6.4.2.3. Australia

6.4.2.3.1. Australia head & neck cancer drugs market, by drug class
6.4.2.3.2. Australia head & neck cancer drugs market, by sales channel

6.4.2.4. India

6.4.2.4.1. India head & neck cancer drugs market, by drug class
6.4.2.4.2. India head & neck cancer drugs market, by sales channel

6.4.2.5. South Korea

6.4.2.5.1. South Korea head & neck cancer drugs market, by drug class
6.4.2.5.2. South Korea head & neck cancer drugs market, by sales channel

6.4.2.6. Rest of Asia-Pacific

6.4.2.6.1. Rest of Asia-Pacific head & neck cancer drugs market, by drug class
6.4.2.6.2. Rest of Asia-Pacific head & neck cancer drugs market, by sales channel

6.4.3. Asia-Pacific market size and forecast, by type
6.4.4. Asia-Pacific market size and forecast, by sales channel

6.5. LAMEA

6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country

6.5.2.1. Brazil

6.5.2.1.1. Brazil head & neck cancer drugs market, by drug class
6.5.2.1.2. Brazil head & neck cancer drugs market, by sales channel

6.5.2.2. Saudi Arabia

6.5.2.2.1. Saudi Arabia head & neck cancer drugs market, by drug class
6.5.2.2.2. Saudi Arabia head & neck cancer drugs market, by sales channel

6.5.2.3. South Africa

6.5.2.3.1. South Africa head & neck cancer drugs market, by drug class
6.5.2.3.2. South Africa head & neck cancer drugs market, by sales channel

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Rest of LAMEA head & neck cancer drugs market, by drug class
6.5.2.4.2. Rest of LAMEA head & neck cancer drugs market, by sales channel

6.5.3. LAMEA market size and forecast, by type
6.5.4. LAMEA market size and forecast, by sales channel

CHAPTER 7: COMPANY PROFILES

7.1. AstraZeneca Plc.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance

7.2. Bristol-Myers Squibb Company

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. Eli Lilly and Company

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product Portfolio
7.3.5. Business performance

7.4. F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance

7.5. Fresenius Medical Care AG & Co. KGaA

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product Portfolio
7.5.5. Business performance

7.6. Merck & Co., Inc.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product Portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. Pfizer Inc.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product Portfolio
7.7.5. Business performance

7.8. Sanofi

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. Sun Pharmaceutical Industries Ltd.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance

7.10. Teva Pharmaceutical Industries Limited

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
7.10.6.Key strategic moves and developments"
 

Select License Type
  • Single User License $5370 USD
  • Multi-User License $6450 USD
  • Corporate User License $8995 USD

Our Clients

  • +1 518-300-1215Mon-Fri, 24Hrs
  • [email protected]We reply within an hours
  • Albany,
    NY, USA.